Skip to main content

Table 2 Summary of patients' baseline characteristics (median values, except where indicated): safety population.

From: Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

 

C.E.R.A. dose group (μg/kg QW)

C.E.R.A. dose group (μg/kg Q3W)

 

0.7

1.4

2.1

2.1

4.2

6.3

Number of patients randomized

36

37

36

37

37

35

Sex, n, (%)

      

   Male

23 (64)

22 (59)

26 (72)

22 (59)

20 (54)

28 (80)

   Female

13 (36)

15 (41)

10 (28)

15 (41)

17 (46)

7 (20)

Age, y (range)

66 (52–80)

65 (41–83)

66 (50–83)

63 (41–91)

63 (24–84)

64 (33–81)

Body weight, kg (range)

71 (41–127)

70 (39–102)

71 (41–91)

66 (36–90)

66 (39–89)

72 (47–100)

Disease stage, n, (%)

      

   IIIB

9 (25)

10 (27)

9 (26)

13 (38)

11 (30)

4 (12)

   IV

27 (75)

27 (73)

26 (74)

21 (62)

26 (70)

30 (88)

Previous treatment before study entry, n, (%)

      

   Chemotherapy

32 (89)

35 (95)

30 (86)

33 (97)

34 (92)

31 (91)

   Surgery

13 (36)

10 (27)

7 (20)

8 (24)

11 (30)

9 (26)

   Radiotherapy

10 (28)

10 (27)

6 (17)

8 (24)

14 (38)

10 (29)

   ESA

0

2 (5)

1 (3)

0

1 (3)

2 (6)

Hb level, g/dL (range)

10.2 (7.1–13.9)

10.2 (8.1–12.8)

10.3 (3.5–12.7)

10.4 (6.8–13.3)

10.1 (8.0–12.9)

10.6 (8.0–14.0)

Serum ferritin level, ng/mL (range)

350 (55–2188)

439 (48–1231)

285 (65–1403)

502 (92–1718)

472 (90–1225)

507 (79–1561)

  1. C.E.R.A.: Continuous Erythropoietin Receptor Activator.
  2. ESA: erythropoiesis-stimulating agent.
  3. Hb: hemoglobin.
  4. QW: once weekly.
  5. Q3W: once every 3 weeks.